Psychedelic Alpha

Introducing Pα+ We're launching a reader-supported model for our more analysis-focused content such as Psychedelic Bulletins, deep dives and interviews. Read the announcement, and subscribe at a discounted launch rate, here: psychedelicalpha.com/news/introduci…

Bloomberg" Quicker Psychedelic Drugs Offer Investors a Better Trip ft. data from Psychedelic Alpha. bloomberg.com/opinion/articl…

A great writeup of the science at #GRCPsychedelics by @JasterAlaina 🔥

Dispatch: The Neurobiology of Psychedelics Gordon Research Conference (Part 1) 200 psychedelic scientists met in Rhode Island to discuss the field via the first Gordon Research Conference on psychedelics. Read more: psychedelicalpha.com/news/dispatch-…

FDA Maintains Clinical Hold on GH Research’s U.S. 5-MeO-DMT IND GH is in a close race with Beckley Psytech, which should soon merge with atai Life Sciences, to launch a pivotal program for the same underlying drug and indication.

FDA Maintains Clinical Hold on GH Research's U.S. Trial $GHRS cannot commence studies in the U.S. as FDA requests further information on respiratory tract histology findings. GH is racing $ATAI/Beckley Psytech to launch the world's first Phase 3 program of 5-MeO-DMT, both…

Montana’s Experimental Treatment Centers Could Offer Drugs Based on Phase I Data Alone Read more in Bulletin 203: psychedelicalpha.com/news/p%CE%B1-p…

Oregon Service Center Licenses: Growth Amid Closures Despite an upward trend in approvals, only 25 of the 34 licensed psilocybin service centers remain operational, marking the closure of 9 centers since early 2024. Explore: psychedelicalpha.com/news/oregon-ps…

Q3 2025: Psychedelic Investor Survey If you have invested in, or are considering investing in, a psychedelics-related company, please complete our latest Psychedelic Investor Survey. docs.google.com/forms/d/1T_rhT…

Oregon Psilocybin Services In-Person OPS Model Presents Barriers for Homebound Clients DOPS’s in-person requirement may be limiting access for homebound individuals, raising concerns about equitable service reach. Explore: psychedelicalpha.com/news/oregon-ps…

Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution We spoke to @TheBorisLab about the study. Read more in Bulletin 203: psychedelicalpha.com/news/p%CE%B1-p…

Breaking: $414M in Spravato revenue in Q2'25, up 53% vs. Q2'24. That puts the esketamine nasal spray on track to bring in $1.7bn this year.

Oregon Psilocybin Services Demand Highest in Western and Urban Counties Service centers are largely concentrated in urban zones - where awareness, access, and socioeconomic resources tend to be higher. Explore: psychedelicalpha.com/news/oregon-ps…

Transcend Scores Breakthrough Therapy Designation for Methylone Transcend Therapeutics has been granted Breakthrough Therapy Designation (BTD) by the FDA for its methylone candidate (TSND-201) for PTSD. Read more in Bulletin 203: psychedelicalpha.com/news/p%CE%B1-p…

Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression Read more in Bulletin 203: psychedelicalpha.com/news/p%CE%B1-p…

Pα+ Psychedelic Bulletin #203: 🔑 Above the Paywall: Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression 📊 Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers 🐁 Longevity Crowd Hypes Psilocybin Study But…

Oregon Psilocybin Services Use Driven by Mental Health and Personal Growth Clients are seeking OPS with diverse intentions, but self-exploration and mental health remain leading drivers. Explore: psychedelicalpha.com/news/oregon-ps…

Big thank you to contributors for supporting speakers and early-career travel awards. 🙏 @OneMindOrg @ACSPublications @ACSChemNeurosci @Psyched_Alpha @mindmedco @Engrail_Tx @JHPsychedelics @SinaiBrain @Xylo_Bio @PsyPharmacists @CoherentCorp @GilgameshRX @UMconsciousness @UWTCRPS

Former Senator Kyrsten Sinema thinks that the current U.S. administration represents a period of opportunity for psychedelic drug developers to have their products approved by the FDA. Read the Interview: psychedelicalpha.com/news/from-sena…

I spy @Psyched_Alpha merch 👀

Former Senator Kyrsten Sinema hopes that Lykos Therapeutics will 'shore up' its data and resubmit its new drug application for MDMA in PTSD. Read the Interview: psychedelicalpha.com/news/from-sena…